Global Gadopentetate Dimeglumine Market

Gadopentetate Dimeglumine Comprehensive Study by End-User (Hospitals, Clinics), Dosage (10ml: 4.69g, 12ml: 5.63g, 15ml: 7.04g, Others) Players and Region - Global Market Outlook to 2030

Gadopentetate Dimeglumine Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Gadopentetate Dimeglumine
The contrast agent gadopentetate dimeglumine has magnetic properties. It is used in conjunction with magnetic resonance imaging (MRI) to enhance the visibility of blood vessels, lungs, and other non-bony tissues on the MRI. Gadopentetate dimeglumine is used to diagnose some brain, blood vessel, and spin disorders (central nervous system). It's used to help with imaging of blood vessels, as well as inflamed or diseased tissue where blood vessels have been "leaky." It is often used for viewing intracranial lesions with irregular vascularity or anomalies in the blood–brain barrierIt's typically given as an intravenous injection. The gadolinium contrast medium Gd-DTPA is classified as an acyclic, ionic gadolinium contrast medium. Its paramagnetic property decreases the T1 relaxation time (and to a lesser degree the T2 and T2* relaxation times) in NMR, which is why it's useful in medicine. Increased incidences of chronic diseases, the demand for image-guided procedures and diagnostics, and a large number of contrast agent approvals are all driving the growth of the contrast media industry. The use of image-guided procedures will aid in determining whether a cancer is malignant or benign. With the rising prevalence and number of cancer cases in both emerging and developed economies around the world, protocols that can assist patients in receiving a diagnosis at an earlier stage are required.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that Asia Pacific Players will contribute the maximum growth to Global Gadopentetate Dimeglumine market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Bayer Ag (Germany), Bracco Diagnostic Inc. (Italy), GE Healthcare (United States), Guerbet Group (France), Spago Nanomedical AB (Sweden), Takeda Pharmaceutical, Fuji Pharma (Japan), BeiLu Pharma (China), J.B. Chemicals and Pharmaceuticals (India) and Lantheus Medical Imaging Inc. (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Towaseiyaku Pharmaceutical (Japan), Hikari Pharmaceutical (Japan) and Sanochemia (Austria).

Segmentation Overview
AMA Research has segmented the market of Global Gadopentetate Dimeglumine market by and Region.



On the basis of geography, the market of Gadopentetate Dimeglumine has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by End-User, the sub-segment i.e. Hospitals will boost the Gadopentetate Dimeglumine market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Dosage, the sub-segment i.e. 10ml: 4.69g will boost the Gadopentetate Dimeglumine market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Technological Advancements in Imaging Solutions and Increasing Demand for Early Diagnosis and Rise of MRI Examinations

Market Growth Drivers:
Increasing Prevalence of Cancer and other Diseases that Require Medical Imaging

Challenges:
High cost of Injectors, Consumables, and Accessories and Need of Various Regulatory Approvals

Restraints:
Several Side Effects Including Joint pains, Skin Discoloration, Headache etc.

Opportunities:
Increased Investment in R&D

Market Leaders and their expansionary development strategies
In September 2022, Bracco Diagnostics Inc., the United States subsidiary of Bracco Imaging S.p.A., announced that the U.S. Food and Drug Administration (FDA) has approved Gadopiclenol Injection, a new, highly stable macrocyclic gadolinium-based contrast agent.
December 2018 – Bracco Diagnostics Inc. Receives U.S. Food And Drug Administration (FDA) Approval for Use of Multihance (GadobenateDimeglumine) Injection, 529 Mg/Ml in Magnetic Resonance Imaging (MRI) of the Central Nervous System (CNS) in Pediatric Patients Younger Than 2 Years


Key Target Audience
Manufacturers of Gadopentetate Dimeglumine, Suppliers of Gadopentetate Dimeglumine, Wholesalers, Distributors and Retailers ofGadopentetate Dimeglumine, Pharmaceutical Companies, Medical Research Institutes and Governmental Bodies

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By End-User
  • Hospitals
  • Clinics

By Dosage
  • 10ml: 4.69g
  • 12ml: 5.63g
  • 15ml: 7.04g
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Prevalence of Cancer and other Diseases that Require Medical Imaging
    • 3.3. Market Challenges
      • 3.3.1. High cost of Injectors, Consumables, and Accessories
      • 3.3.2. Need of Various Regulatory Approvals
    • 3.4. Market Trends
      • 3.4.1. Technological Advancements in Imaging Solutions
      • 3.4.2. Increasing Demand for Early Diagnosis and Rise of MRI Examinations
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Gadopentetate Dimeglumine, by End-User, Dosage and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Gadopentetate Dimeglumine (Value)
      • 5.2.1. Global Gadopentetate Dimeglumine by: End-User (Value)
        • 5.2.1.1. Hospitals
        • 5.2.1.2. Clinics
      • 5.2.2. Global Gadopentetate Dimeglumine by: Dosage (Value)
        • 5.2.2.1. 10ml: 4.69g
        • 5.2.2.2. 12ml: 5.63g
        • 5.2.2.3. 15ml: 7.04g
        • 5.2.2.4. Others
      • 5.2.3. Global Gadopentetate Dimeglumine Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
  • 6. Gadopentetate Dimeglumine: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Bayer Ag (Germany)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Bracco Diagnostic Inc. (Italy)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. GE Healthcare (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Guerbet Group (France)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Spago Nanomedical AB (Sweden)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Takeda Pharmaceutical
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Fuji Pharma (Japan)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. BeiLu Pharma (China)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. J.B. Chemicals and Pharmaceuticals (India)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Lantheus Medical Imaging Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Gadopentetate Dimeglumine Sale, by End-User, Dosage and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Gadopentetate Dimeglumine (Value)
      • 7.2.1. Global Gadopentetate Dimeglumine by: End-User (Value)
        • 7.2.1.1. Hospitals
        • 7.2.1.2. Clinics
      • 7.2.2. Global Gadopentetate Dimeglumine by: Dosage (Value)
        • 7.2.2.1. 10ml: 4.69g
        • 7.2.2.2. 12ml: 5.63g
        • 7.2.2.3. 15ml: 7.04g
        • 7.2.2.4. Others
      • 7.2.3. Global Gadopentetate Dimeglumine Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Gadopentetate Dimeglumine: by End-User(USD Million)
  • Table 2. Gadopentetate Dimeglumine Hospitals , by Region USD Million (2018-2023)
  • Table 3. Gadopentetate Dimeglumine Clinics , by Region USD Million (2018-2023)
  • Table 4. Gadopentetate Dimeglumine: by Dosage(USD Million)
  • Table 5. Gadopentetate Dimeglumine 10ml: 4.69g , by Region USD Million (2018-2023)
  • Table 6. Gadopentetate Dimeglumine 12ml: 5.63g , by Region USD Million (2018-2023)
  • Table 7. Gadopentetate Dimeglumine 15ml: 7.04g , by Region USD Million (2018-2023)
  • Table 8. Gadopentetate Dimeglumine Others , by Region USD Million (2018-2023)
  • Table 9. South America Gadopentetate Dimeglumine, by Country USD Million (2018-2023)
  • Table 10. South America Gadopentetate Dimeglumine, by End-User USD Million (2018-2023)
  • Table 11. South America Gadopentetate Dimeglumine, by Dosage USD Million (2018-2023)
  • Table 12. Brazil Gadopentetate Dimeglumine, by End-User USD Million (2018-2023)
  • Table 13. Brazil Gadopentetate Dimeglumine, by Dosage USD Million (2018-2023)
  • Table 14. Argentina Gadopentetate Dimeglumine, by End-User USD Million (2018-2023)
  • Table 15. Argentina Gadopentetate Dimeglumine, by Dosage USD Million (2018-2023)
  • Table 16. Rest of South America Gadopentetate Dimeglumine, by End-User USD Million (2018-2023)
  • Table 17. Rest of South America Gadopentetate Dimeglumine, by Dosage USD Million (2018-2023)
  • Table 18. Asia Pacific Gadopentetate Dimeglumine, by Country USD Million (2018-2023)
  • Table 19. Asia Pacific Gadopentetate Dimeglumine, by End-User USD Million (2018-2023)
  • Table 20. Asia Pacific Gadopentetate Dimeglumine, by Dosage USD Million (2018-2023)
  • Table 21. China Gadopentetate Dimeglumine, by End-User USD Million (2018-2023)
  • Table 22. China Gadopentetate Dimeglumine, by Dosage USD Million (2018-2023)
  • Table 23. Japan Gadopentetate Dimeglumine, by End-User USD Million (2018-2023)
  • Table 24. Japan Gadopentetate Dimeglumine, by Dosage USD Million (2018-2023)
  • Table 25. India Gadopentetate Dimeglumine, by End-User USD Million (2018-2023)
  • Table 26. India Gadopentetate Dimeglumine, by Dosage USD Million (2018-2023)
  • Table 27. South Korea Gadopentetate Dimeglumine, by End-User USD Million (2018-2023)
  • Table 28. South Korea Gadopentetate Dimeglumine, by Dosage USD Million (2018-2023)
  • Table 29. Taiwan Gadopentetate Dimeglumine, by End-User USD Million (2018-2023)
  • Table 30. Taiwan Gadopentetate Dimeglumine, by Dosage USD Million (2018-2023)
  • Table 31. Australia Gadopentetate Dimeglumine, by End-User USD Million (2018-2023)
  • Table 32. Australia Gadopentetate Dimeglumine, by Dosage USD Million (2018-2023)
  • Table 33. Rest of Asia-Pacific Gadopentetate Dimeglumine, by End-User USD Million (2018-2023)
  • Table 34. Rest of Asia-Pacific Gadopentetate Dimeglumine, by Dosage USD Million (2018-2023)
  • Table 35. Europe Gadopentetate Dimeglumine, by Country USD Million (2018-2023)
  • Table 36. Europe Gadopentetate Dimeglumine, by End-User USD Million (2018-2023)
  • Table 37. Europe Gadopentetate Dimeglumine, by Dosage USD Million (2018-2023)
  • Table 38. Germany Gadopentetate Dimeglumine, by End-User USD Million (2018-2023)
  • Table 39. Germany Gadopentetate Dimeglumine, by Dosage USD Million (2018-2023)
  • Table 40. France Gadopentetate Dimeglumine, by End-User USD Million (2018-2023)
  • Table 41. France Gadopentetate Dimeglumine, by Dosage USD Million (2018-2023)
  • Table 42. Italy Gadopentetate Dimeglumine, by End-User USD Million (2018-2023)
  • Table 43. Italy Gadopentetate Dimeglumine, by Dosage USD Million (2018-2023)
  • Table 44. United Kingdom Gadopentetate Dimeglumine, by End-User USD Million (2018-2023)
  • Table 45. United Kingdom Gadopentetate Dimeglumine, by Dosage USD Million (2018-2023)
  • Table 46. Netherlands Gadopentetate Dimeglumine, by End-User USD Million (2018-2023)
  • Table 47. Netherlands Gadopentetate Dimeglumine, by Dosage USD Million (2018-2023)
  • Table 48. Rest of Europe Gadopentetate Dimeglumine, by End-User USD Million (2018-2023)
  • Table 49. Rest of Europe Gadopentetate Dimeglumine, by Dosage USD Million (2018-2023)
  • Table 50. MEA Gadopentetate Dimeglumine, by Country USD Million (2018-2023)
  • Table 51. MEA Gadopentetate Dimeglumine, by End-User USD Million (2018-2023)
  • Table 52. MEA Gadopentetate Dimeglumine, by Dosage USD Million (2018-2023)
  • Table 53. Middle East Gadopentetate Dimeglumine, by End-User USD Million (2018-2023)
  • Table 54. Middle East Gadopentetate Dimeglumine, by Dosage USD Million (2018-2023)
  • Table 55. Africa Gadopentetate Dimeglumine, by End-User USD Million (2018-2023)
  • Table 56. Africa Gadopentetate Dimeglumine, by Dosage USD Million (2018-2023)
  • Table 57. North America Gadopentetate Dimeglumine, by Country USD Million (2018-2023)
  • Table 58. North America Gadopentetate Dimeglumine, by End-User USD Million (2018-2023)
  • Table 59. North America Gadopentetate Dimeglumine, by Dosage USD Million (2018-2023)
  • Table 60. United States Gadopentetate Dimeglumine, by End-User USD Million (2018-2023)
  • Table 61. United States Gadopentetate Dimeglumine, by Dosage USD Million (2018-2023)
  • Table 62. Canada Gadopentetate Dimeglumine, by End-User USD Million (2018-2023)
  • Table 63. Canada Gadopentetate Dimeglumine, by Dosage USD Million (2018-2023)
  • Table 64. Mexico Gadopentetate Dimeglumine, by End-User USD Million (2018-2023)
  • Table 65. Mexico Gadopentetate Dimeglumine, by Dosage USD Million (2018-2023)
  • Table 66. Company Basic Information, Sales Area and Its Competitors
  • Table 67. Company Basic Information, Sales Area and Its Competitors
  • Table 68. Company Basic Information, Sales Area and Its Competitors
  • Table 69. Company Basic Information, Sales Area and Its Competitors
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Company Basic Information, Sales Area and Its Competitors
  • Table 76. Gadopentetate Dimeglumine: by End-User(USD Million)
  • Table 77. Gadopentetate Dimeglumine Hospitals , by Region USD Million (2025-2030)
  • Table 78. Gadopentetate Dimeglumine Clinics , by Region USD Million (2025-2030)
  • Table 79. Gadopentetate Dimeglumine: by Dosage(USD Million)
  • Table 80. Gadopentetate Dimeglumine 10ml: 4.69g , by Region USD Million (2025-2030)
  • Table 81. Gadopentetate Dimeglumine 12ml: 5.63g , by Region USD Million (2025-2030)
  • Table 82. Gadopentetate Dimeglumine 15ml: 7.04g , by Region USD Million (2025-2030)
  • Table 83. Gadopentetate Dimeglumine Others , by Region USD Million (2025-2030)
  • Table 84. South America Gadopentetate Dimeglumine, by Country USD Million (2025-2030)
  • Table 85. South America Gadopentetate Dimeglumine, by End-User USD Million (2025-2030)
  • Table 86. South America Gadopentetate Dimeglumine, by Dosage USD Million (2025-2030)
  • Table 87. Brazil Gadopentetate Dimeglumine, by End-User USD Million (2025-2030)
  • Table 88. Brazil Gadopentetate Dimeglumine, by Dosage USD Million (2025-2030)
  • Table 89. Argentina Gadopentetate Dimeglumine, by End-User USD Million (2025-2030)
  • Table 90. Argentina Gadopentetate Dimeglumine, by Dosage USD Million (2025-2030)
  • Table 91. Rest of South America Gadopentetate Dimeglumine, by End-User USD Million (2025-2030)
  • Table 92. Rest of South America Gadopentetate Dimeglumine, by Dosage USD Million (2025-2030)
  • Table 93. Asia Pacific Gadopentetate Dimeglumine, by Country USD Million (2025-2030)
  • Table 94. Asia Pacific Gadopentetate Dimeglumine, by End-User USD Million (2025-2030)
  • Table 95. Asia Pacific Gadopentetate Dimeglumine, by Dosage USD Million (2025-2030)
  • Table 96. China Gadopentetate Dimeglumine, by End-User USD Million (2025-2030)
  • Table 97. China Gadopentetate Dimeglumine, by Dosage USD Million (2025-2030)
  • Table 98. Japan Gadopentetate Dimeglumine, by End-User USD Million (2025-2030)
  • Table 99. Japan Gadopentetate Dimeglumine, by Dosage USD Million (2025-2030)
  • Table 100. India Gadopentetate Dimeglumine, by End-User USD Million (2025-2030)
  • Table 101. India Gadopentetate Dimeglumine, by Dosage USD Million (2025-2030)
  • Table 102. South Korea Gadopentetate Dimeglumine, by End-User USD Million (2025-2030)
  • Table 103. South Korea Gadopentetate Dimeglumine, by Dosage USD Million (2025-2030)
  • Table 104. Taiwan Gadopentetate Dimeglumine, by End-User USD Million (2025-2030)
  • Table 105. Taiwan Gadopentetate Dimeglumine, by Dosage USD Million (2025-2030)
  • Table 106. Australia Gadopentetate Dimeglumine, by End-User USD Million (2025-2030)
  • Table 107. Australia Gadopentetate Dimeglumine, by Dosage USD Million (2025-2030)
  • Table 108. Rest of Asia-Pacific Gadopentetate Dimeglumine, by End-User USD Million (2025-2030)
  • Table 109. Rest of Asia-Pacific Gadopentetate Dimeglumine, by Dosage USD Million (2025-2030)
  • Table 110. Europe Gadopentetate Dimeglumine, by Country USD Million (2025-2030)
  • Table 111. Europe Gadopentetate Dimeglumine, by End-User USD Million (2025-2030)
  • Table 112. Europe Gadopentetate Dimeglumine, by Dosage USD Million (2025-2030)
  • Table 113. Germany Gadopentetate Dimeglumine, by End-User USD Million (2025-2030)
  • Table 114. Germany Gadopentetate Dimeglumine, by Dosage USD Million (2025-2030)
  • Table 115. France Gadopentetate Dimeglumine, by End-User USD Million (2025-2030)
  • Table 116. France Gadopentetate Dimeglumine, by Dosage USD Million (2025-2030)
  • Table 117. Italy Gadopentetate Dimeglumine, by End-User USD Million (2025-2030)
  • Table 118. Italy Gadopentetate Dimeglumine, by Dosage USD Million (2025-2030)
  • Table 119. United Kingdom Gadopentetate Dimeglumine, by End-User USD Million (2025-2030)
  • Table 120. United Kingdom Gadopentetate Dimeglumine, by Dosage USD Million (2025-2030)
  • Table 121. Netherlands Gadopentetate Dimeglumine, by End-User USD Million (2025-2030)
  • Table 122. Netherlands Gadopentetate Dimeglumine, by Dosage USD Million (2025-2030)
  • Table 123. Rest of Europe Gadopentetate Dimeglumine, by End-User USD Million (2025-2030)
  • Table 124. Rest of Europe Gadopentetate Dimeglumine, by Dosage USD Million (2025-2030)
  • Table 125. MEA Gadopentetate Dimeglumine, by Country USD Million (2025-2030)
  • Table 126. MEA Gadopentetate Dimeglumine, by End-User USD Million (2025-2030)
  • Table 127. MEA Gadopentetate Dimeglumine, by Dosage USD Million (2025-2030)
  • Table 128. Middle East Gadopentetate Dimeglumine, by End-User USD Million (2025-2030)
  • Table 129. Middle East Gadopentetate Dimeglumine, by Dosage USD Million (2025-2030)
  • Table 130. Africa Gadopentetate Dimeglumine, by End-User USD Million (2025-2030)
  • Table 131. Africa Gadopentetate Dimeglumine, by Dosage USD Million (2025-2030)
  • Table 132. North America Gadopentetate Dimeglumine, by Country USD Million (2025-2030)
  • Table 133. North America Gadopentetate Dimeglumine, by End-User USD Million (2025-2030)
  • Table 134. North America Gadopentetate Dimeglumine, by Dosage USD Million (2025-2030)
  • Table 135. United States Gadopentetate Dimeglumine, by End-User USD Million (2025-2030)
  • Table 136. United States Gadopentetate Dimeglumine, by Dosage USD Million (2025-2030)
  • Table 137. Canada Gadopentetate Dimeglumine, by End-User USD Million (2025-2030)
  • Table 138. Canada Gadopentetate Dimeglumine, by Dosage USD Million (2025-2030)
  • Table 139. Mexico Gadopentetate Dimeglumine, by End-User USD Million (2025-2030)
  • Table 140. Mexico Gadopentetate Dimeglumine, by Dosage USD Million (2025-2030)
  • Table 141. Research Programs/Design for This Report
  • Table 142. Key Data Information from Secondary Sources
  • Table 143. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Gadopentetate Dimeglumine: by End-User USD Million (2018-2023)
  • Figure 5. Global Gadopentetate Dimeglumine: by Dosage USD Million (2018-2023)
  • Figure 6. South America Gadopentetate Dimeglumine Share (%), by Country
  • Figure 7. Asia Pacific Gadopentetate Dimeglumine Share (%), by Country
  • Figure 8. Europe Gadopentetate Dimeglumine Share (%), by Country
  • Figure 9. MEA Gadopentetate Dimeglumine Share (%), by Country
  • Figure 10. North America Gadopentetate Dimeglumine Share (%), by Country
  • Figure 11. Global Gadopentetate Dimeglumine share by Players 2023 (%)
  • Figure 12. Global Gadopentetate Dimeglumine share by Players (Top 3) 2023(%)
  • Figure 13. Global Gadopentetate Dimeglumine share by Players (Top 5) 2023(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. Bayer Ag (Germany) Revenue, Net Income and Gross profit
  • Figure 16. Bayer Ag (Germany) Revenue: by Geography 2023
  • Figure 17. Bracco Diagnostic Inc. (Italy) Revenue, Net Income and Gross profit
  • Figure 18. Bracco Diagnostic Inc. (Italy) Revenue: by Geography 2023
  • Figure 19. GE Healthcare (United States) Revenue, Net Income and Gross profit
  • Figure 20. GE Healthcare (United States) Revenue: by Geography 2023
  • Figure 21. Guerbet Group (France) Revenue, Net Income and Gross profit
  • Figure 22. Guerbet Group (France) Revenue: by Geography 2023
  • Figure 23. Spago Nanomedical AB (Sweden) Revenue, Net Income and Gross profit
  • Figure 24. Spago Nanomedical AB (Sweden) Revenue: by Geography 2023
  • Figure 25. Takeda Pharmaceutical Revenue, Net Income and Gross profit
  • Figure 26. Takeda Pharmaceutical Revenue: by Geography 2023
  • Figure 27. Fuji Pharma (Japan) Revenue, Net Income and Gross profit
  • Figure 28. Fuji Pharma (Japan) Revenue: by Geography 2023
  • Figure 29. BeiLu Pharma (China) Revenue, Net Income and Gross profit
  • Figure 30. BeiLu Pharma (China) Revenue: by Geography 2023
  • Figure 31. J.B. Chemicals and Pharmaceuticals (India) Revenue, Net Income and Gross profit
  • Figure 32. J.B. Chemicals and Pharmaceuticals (India) Revenue: by Geography 2023
  • Figure 33. Lantheus Medical Imaging Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 34. Lantheus Medical Imaging Inc. (United States) Revenue: by Geography 2023
  • Figure 35. Global Gadopentetate Dimeglumine: by End-User USD Million (2025-2030)
  • Figure 36. Global Gadopentetate Dimeglumine: by Dosage USD Million (2025-2030)
  • Figure 37. South America Gadopentetate Dimeglumine Share (%), by Country
  • Figure 38. Asia Pacific Gadopentetate Dimeglumine Share (%), by Country
  • Figure 39. Europe Gadopentetate Dimeglumine Share (%), by Country
  • Figure 40. MEA Gadopentetate Dimeglumine Share (%), by Country
  • Figure 41. North America Gadopentetate Dimeglumine Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Bayer Ag (Germany)
  • Bracco Diagnostic Inc. (Italy)
  • GE Healthcare (United States)
  • Guerbet Group (France)
  • Spago Nanomedical AB (Sweden)
  • Takeda Pharmaceutical
  • Fuji Pharma (Japan)
  • BeiLu Pharma (China)
  • J.B. Chemicals and Pharmaceuticals (India)
  • Lantheus Medical Imaging Inc. (United States)
Additional players considered in the study are as follows:
Towaseiyaku Pharmaceutical (Japan) , Hikari Pharmaceutical (Japan) , Sanochemia (Austria)
Select User Access Type

Key Highlights of Report


Feb 2024 203 Pages 61 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Gadopentetate Dimeglumine Market Quantitative research analysis
Global Gadopentetate Dimeglumine Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Bayer Ag (Germany), Bracco Diagnostic Inc. (Italy), GE Healthcare (United States), Guerbet Group (France), Spago Nanomedical AB (Sweden), Takeda Pharmaceutical, Fuji Pharma (Japan), BeiLu Pharma (China), J.B. Chemicals and Pharmaceuticals (India) and Lantheus Medical Imaging Inc. (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Technological Advancements in Imaging Solutions " is seen as one of major influencing trends for Gadopentetate Dimeglumine Market during projected period 2023-2030.
The Gadopentetate Dimeglumine market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Gadopentetate Dimeglumine Market Report?

Have a Query? Click Here

Other Related Reports

Signal Transduction Inhibitors Comprehensive Study by Type (Dasatinib, Erlotinib, Gefitinib, Imatinib, Lapatinib, Nilotinib, Pazopanib, Sorafenib, Sunitinib), Application (Lung Cancer, Prostate Cance...
$ 3750
Pediatric Growth Hormones Comprehensive Study by Route of Administration (Intravenous, Intramuscular, Subcutaneous, Oral), Indication (Growth Hormone Deficiency, Turner Syndrome, Renal Insufficiency,...
$ 3650
Bovine Ephemeral Fever Vaccines Comprehensive Study by Application (Cattle, Buffaloes), Vaccine Type (Live Vaccine, Killed Vaccine), End User (Medical Device Companies, Pharmaceutical industries, An...
$ 3650
Dental Resin Composites Comprehensive Study by Type (Bulk fill composite, Universal composite, Flowable composite, Others), Application (Dental fillings, Dental crowns, Dental bridges, Others), Compo...
$ 3750
Ocaliva Comprehensive Study by Application (Primary Biliary Cirrhosis, Non-alcoholic Fatty Liver Disease, Other), Distribution Channel (Online, Offline), End-User (Hospitals, Cancer Centres, Others),...
$ 3350
Lithium Medication Comprehensive Study by Type (Tablets, Capsules, Oral Solution), Application (Hospitals, Clinics, Others), Distribution Channel (Online Pharmacies, Retail Pharmacies, Online, Others...
$ 3500